Literature DB >> 15471943

The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways.

J A Koehler1, B Yusta, D J Drucker.   

Abstract

Glucagon-like peptide-2 (GLP-2) regulates proliferative and cytoprotective pathways in the intestine; however GLP-2 receptor (GLP-2R) signal transduction remains poorly understood, and cell lines that express the endogenous GLP-2R have not yet been isolated. We have now identified several expressed sequence tags from human cervical carcinoma cDNA libraries that correspond to GLP-2R nucleotide sequences. GLP-2R mRNA transcripts were detected by RT-PCR in two human cervical carcinoma cell lines, including HeLa cells. GLP-2 increased cAMP accumulation and activated ERK1/2 in HeLa cells transiently expressing the cloned human HeLa cell GLP-2R cDNA. However, the GLP-2R-induced activation of ERK1/2 was not mediated through Galphas, adenylyl cyclase, or transactivation of the epidermal growth factor receptor, but was pertussis toxin sensitive, inhibited by dominant negative Ras, and dependent on betagamma-subunits. GLP-2 also induced a significant increase in bromodeoxyuridine incorporation that was blocked by dominant negative Ras. Furthermore, GLP-2 inhibited HeLa cell apoptosis induced by LY294002 in a protein kinase A-dependent, but ERK-independent, manner. These findings demonstrate that the HeLa cell GLP-2R differentially signals through both Galphas/cAMP- and Gi/Go-dependent pathways, illustrating for the first time that the GLP-2R is capable of coupling to multiple heterotrimeric G proteins defining distinct GLP-2R-dependent biological actions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471943     DOI: 10.1210/me.2004-0196

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  11 in total

1.  Glucagon-like peptide-2 (GLP-2) modulates the cGMP signalling pathway by regulating the expression of the soluble guanylyl cyclase receptor subunits in cultured rat astrocytes.

Authors:  Esther Velázquez; Enrique Blázquez; Juan Miguel Ruiz-Albusac
Journal:  Mol Neurobiol       Date:  2012-07-18       Impact factor: 5.590

Review 2.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts.

Authors:  Jason L S Leen; Angelo Izzo; Chandani Upadhyay; Katherine J Rowland; Philip E Dubé; Steven Gu; Scott P Heximer; Christopher J Rhodes; Daniel R Storm; P Kay Lund; Patricia L Brubaker
Journal:  Endocrinology       Date:  2010-12-15       Impact factor: 4.736

4.  Glucagon-like peptide-2 protects impaired intestinal mucosal barriers in obstructive jaundice rats.

Authors:  Jun Chen; Jia-Tian Dong; Xiao-Jing Li; Ye Gu; Zhi-Jian Cheng; Yuan-Kun Cai
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

5.  Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis.

Authors:  Seung-Jun Lee; Jennifer Lee; Karen K Li; Dianne Holland; Heather Maughan; David S Guttman; Bernardo Yusta; Daniel J Drucker
Journal:  Endocrinology       Date:  2012-01-17       Impact factor: 4.736

6.  Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells.

Authors:  Jacqueline A Koehler; Will Harper; Maja Barnard; Bernardo Yusta; Daniel J Drucker
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

7.  Synergistic effect of glucagon-like peptide 2 (GLP-2) and of key growth factors on the proliferation of cultured rat astrocytes. Evidence for reciprocal upregulation of the mRNAs for GLP-2 and IGF-I receptors.

Authors:  Esther Velázquez; Enrique Blázquez; Juan Miguel Ruiz-Albusac
Journal:  Mol Neurobiol       Date:  2009-08-13       Impact factor: 5.590

Review 8.  Intestinal hormones and growth factors: effects on the small intestine.

Authors:  Laurie Drozdowski; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

9.  Emerging treatment options for short bowel syndrome: potential role of teduglutide.

Authors:  Cheng T Tee; Katharina Wallis; Simon M Gabe
Journal:  Clin Exp Gastroenterol       Date:  2011-08-19

10.  The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain.

Authors:  Congxia Zheng; Linjie Chen; Xiaopan Chen; Xiaobai He; Jingwen Yang; Ying Shi; Naiming Zhou
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.